New Results

Viral neuroinvasion and neurotropism without neuronal damage in the hACE2 mouse model of COVID-19

Frauke Seehusen, Jordan J. Clark, Parul Sharma, Krishanthi Subramaniam, Sabina Wunderlin Giuliani, Grant L. Hughes, Edward I. Patterson, Benedict D. Michael, Andrew Owen, Julian A. Hiscox, James P. Stewart, Anja Kipar
doi: https://doi.org/10.1101/2021.04.16.440173

Abstract

Coronavirus disease 2019 (COVID-19) is a primarily respiratory disease with variable clinical courses for which animal models are needed to gather insights into the pathogenesis of its causative virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in human patients. SARS-CoV-2 not only affects the respiratory tract but also the central nervous system (CNS), leading to neurological symptoms such as loss of smell and taste, headache, fatigue or severe complications like cerebrovascular diseases. Transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) under the cytokeratin 18 promoter (K18-hACE2) represent a well-known model of SARS-CoV-2 infection. In the present study, it served to investigate the spatiotemporal distribution and pathomorphological features in the CNS following intranasal infection with relatively low SARS-CoV-2 doses and after prior influenza A virus infection.

In K18-hACE2 mice, SARS-CoV-2 was found to frequently spread to and within the CNS during the later phase (day 7) of infection. Infection was restricted to neurons and appeared to first affect the olfactory bulb and spread from there mainly in basally orientated regions in the brain and into the spinal cord, in a dose dependent manner and independent of ACE2 expression. Neuronal infection was not associated with cell death, axonal damage or demyelination. However, microglial activation, microgliosis and a mild macrophage and T cell dominated inflammatory response was consistently observed. This was accompanied by apoptotic death of endothelial, microglial and immune cells, without evidence of viral infection of glial cells, endothelial cells and leukocytes.

Taken together, microgliosis and immune cell apoptosis indicate a potential important role of microglial cells for the pathogenesis and viral effect in COVID-19 and possible impairment of neurological functions, especially in long COVID. These data may also be informative for the selection of therapeutic candidates, and broadly support investigation of agents with adequate penetration into relevant regions of the CNS.

Introduction

As of April 2021, the newly emerged betacoronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has infected over 135 million people globally, with over 2.9 million deaths due to the associated disease, COVID-19 (WHO, COVID-19 Weekly Epidemiological Update, 13th April 2021). The majority of COVID-19 patients display respiratory symptoms. However, a proportion of patients develop mostly transient unspecific neurological signs like loss of smell and taste (anosmia, ageusia), headache, or dizziness. Fatal cases can also be associated with ischemic stroke, hemorrhagic encephalopathy and epileptic seizures as well as meningoencephalitis (Bernard-Valnet et al., 2020; Helms et al., 2020a; Huang et al., 2020; Mao et al., 2020; Moriguchi et al., 2020; Oxley et al., 2020; Poyiadji et al., 2020).

There is evidence of viral entry into the brain through the olfactory or vagal nerve and/or the oral and ophthalmic routes, with trans-synaptic neuronal spread to other brain regions (Cantuti-Castelvetri et al., 2020; Matschke et al., 2020; Meinhardt et al., 2021); this could provide a link to the frequently reported (initial) anosmia and ageusia. In addition, hematogenous spread to the brain via infection of endothelial cells and/or immune cells is suspected (Paniz-Mondolfi et al., 2020; Al-Sarraj et al., 2021).

Pathomorphological findings reported in the brain of fatal human COVID-19 cases are variable and present as vascular/hemodynamic/ischemic lesions like ischemic infarcts and/or mild inflammatory changes; neuronal or axonal damage and acute disseminated encephalomyelitis have been reported in rare cases (Deigendesch et al., 2020; Fabbri et al., 2021; Jaunmuktane et al., 2020; Kantonen et al., 2020; Matschke et al, 2020; Schurink et al., 2020; Solomon et al., 2020; Reichard et al., 2020; von Weyhern et al., 2020). Focal or diffuse microglial activation or microglial nodules have also been observed (Al-Dalahmah et al., 2020; Bussani et al., 2020; Deigendesch et al., 2020; Jaunmuktane et al., 2020; Matschke et al., 2020; Schurink et al., 2020; Fabbri et al., 2021). COVID-19 patients can harbor SARS-CoV-2 RNA and protein in the brain (Matschke et al., 2020; Puelles et al., 2020; Meinhardt et al., 2021), and a recent study using human brain organoids provided strong evidence that SARS-CoV-2 replicates in neurons (Song et al., 2021). However, presence of the virus was not found to be associated with the severity of neuropathological changes (Matschke et al., 2020), and in a recent study, immunohistochemical staining for SARS-CoV-2 failed to detect viral antigen in all 18 investigated patients, while low levels of viral RNA were detected by RT-PCR in five patients (Solomon et al., 2020).

Encephalopathy, as a severe complication in COVID-19, is often associated with systemic hyperinflammation mainly provoked by an aberrantly excessive innate immune response (Najjar et al. 2020). It is suspected that not only a direct virus induced endotheliitis, but also a maladaptive innate immune response may impair neurovascular endothelial function and cause disruption of the blood-brain barrier (BBB), activation of innate immune signalling pathways and a parainfectious autoimmunity (Najjar et al., 2020).

Recent articles have discussed the role of glial cells in COVID-19 encephalopathies (Murta et al., 2020; Vargas et al., 2020). Glial cells might not only represent potential targets for viral infection but are also highly sensitive to systemic proinflammatory cytokines (Perry et al., 2007; Teeling and Perry, 2009; Murta et al., 2015; Murta and Ferrari, 2016). In COVID-19 patients, the massive systemic release of inflammatory cytokines could affect endothelial cells and astrocytes of the BBB, thus facilitating viral entry like in other viral brain diseases such as HIV-1 encephalitis and measles (Swanson and McGavern, 2015). Indeed, a recent study has shown that SARS-CoV-2 spike protein S1 from the blood can pass the BBB and thereby gain access to the brain parenchyma in mice, potentially triggering a parenchymal response without the presence of intact virus (Rhea et al., 2021). Furthermore, astrocytes and microglia may contribute to the local neuroinflammatory response of the CNS (Michael et al., 2020; Murta et al., 2020). Also, microglial cells are hypothesized to be involved in the innate immune response and facilitate viral clearance, recruitment of immune cells as well as activation of antiviral responses and cytokine production in the brain of COVID-19 patients (Vargas et al., 2020). Some authors also propose that a SARS-CoV-2-induced proinflammatory microglial phenotype might contribute to the development of subsequent neurodegenerative disorders (Alam et al., 2020; Mahalaxmi et al., 2020). Furthermore, the proinflammatory priming of microglia, either by direct SARS-CoV-2 infection or a peripheral cytokine storm, could exacerbate disease, as indicated in experimental murine coronavirus (MHV-A59) infection (Lavi and Cong, 2020).

The human angiotensin-converting enzyme 2 (hACE2) is considered to be the main host receptor for SARS-CoV-2, binding to the viral spike protein (S) (Hoffmann et al., 2020). The K18-hACE2 transgenic (K18-hACE2) mouse, where hACE2 expression is driven by the epithelial cell cytokeratin-18 (K18) promoter, was developed to study the pathogenesis of SARS-CoV infection (McCray et al., 2007); it is now frequently employed to address a broad range of questions regarding SARS-CoV-2 as expression of human ACE2 (hACE2) appears to convey higher binding affinity than its murine counterpart. Several recent studies have shown that intranasal SARS-CoV-2 infection of K18-hACE2 mice reaches the brain where it spreads widely. Infection of the brain can be associated with non-suppurative (meningo)encephalitis (Carossino et al., 2021; Clark et al., 2021; Kumari et al, 2021; Song et al., 2021). With high infectious doses (105 PFU), very high viral loads were found in the brain at a time when lung burdens had already decreased, in association with upregulation of IFN-α as well as proinflammatory cytokine and chemokine transcription; the authors posited that lethal outcome of infection in these mice was a consequence of neuroinvasion (Kumari et al, 2021). Another study using an even higher viral inoculum (106 PFU) elicited CNS signs (tremors, proprioceptive defects, abnormal gait, imbalance) by day 6/7 after infection (Carossino et al., 2021). Studies in mice have also confirmed that the virus can get access to the brain via the olfactory bulb (Rhea et al., 2020; Song et al., 2021).

Detailed information on the effect of SARS-CoV-2 in the brain of COVID-19 patients has so far been collected from fatal cases. However, there is a current paucity of data relating to what happens in the brain of patients that do not have severe disease, recover from it or develop long COVID-19. A better understanding of the viral dynamics within the CNS will provide further insight into the disease pathology and will be highly informative for therapeutics development by providing insight into the prerequisites for distribution of new medicines in development. The present study represents a first attempt to address this question by investigating the CNS of K18-hACE2 mice after intranasal infection with a low to moderate dose of a SARS-CoV-2 wildtype strain, also in combination with prior influenza A virus infection as it seems to foster neuronal spread (Clark et al., 2021).

Material and Methods

Cell culture and virus

A PANGO lineage B strain of strain of SARS-CoV-2 (hCoV-2/human/Liverpool/REMRQ0001/2020) cultured from a nasopharyngeal swab from a patient, was passaged in Vero E6 cells (Patterson et al., 2020). The fourth virus passage (P4) was used for infections after it had been checked for deletions in the mapped reads and the stock confirmed to not contain any deletions that can occur on passage (Clark et al., 2021).

Influenza virus A/HKx31 (X31, H3N2) was propagated in the allantoic cavity of 9-day-old embryonated chicken eggs at 35 °C. Titres were determined by an influenza plaque assay using MDCK cells (Clark et al., 2021).

Biosafety

All work was performed in accordance with risk assessments and standard operating procedures approved by the University of Liverpool Biohazards Sub-Committee and by the UK Health and Safety Executive. Work with SARS-CoV-2 was performed at containment level 3 by personnel equipped with respirator airstream units with filtered air supply.

Animals and virus infections

Animal work was approved by the local University of Liverpool Animal Welfare and Ethical Review Body and performed under UK Home Office Project Licence PP4715265. Mice carrying the human ACE2 gene under the control of the keratin 18 promoter (K18-hACE2; formally B6.Cg-Tg(K18-ACE2)2Prlmn/J) were purchased from Jackson Laboratories. Mice were maintained under SPF barrier conditions in individually ventilated cages.

Animals were randomly assigned into multiple cohorts. For SARS-CoV-2 infection, mice were anaesthetized lightly with isoflurane and inoculated intra-nasally with 50 μl containing 103 PFU (cohorts 1 and 2) or 104 PFU (cohort 3) SARS-CoV-2 in PBS; control animals received PBS. For double infections (cohort 2), mice were first infected with IAV; they were anaesthetized lightly with KETASET i.m. and inoculated intranasally with 102 PFU IAV X31 in 50 μl sterile PBS. Three days later, they were infected with SARS-CoV-2, as described above. Mock-infected mice served as controls. Mice were monitored for any clinical signs and weighed. Animals were sacrificed at 3 or 7 days post SARS-CoV-2 infection by an overdose of pentabarbitone. Tissues were removed immediately for downstream processing; the lungs were processed for another study (Clark et al., 2021).

Tissue collection, preparation and processing

For the present study, the heads and spinal cords (C1-T12) were collected and fixed in 10% neutral buffered formal saline for 24-48 h. Brains were exenterated and coronal sections prepared. Heads were sawn longitudinally in the midline for histological assessment of the nasal cavity, cribriform plate and rostral parts of the olfactory bulb that had not been removed with the brain. In cases where SARS-CoV-2 viral antigen was detected in the brain (see below), the spinal cords were sawn into appr. 1.5 mm thick cross sections, using a diamond saw (Exakt 300; Exakt). Heads and spinal cord were gently decalcified in RDF (Biosystems) for twice 5 days, at room temperature (RT) and on a shaker. Brains, heads and spinal cords were routinely paraffin wax embedded.

Histology, immunohistology

Consecutive sections (3-5 μm) were either stained with hematoxylin and eosin (HE) or used for immunohistochemistry (IH). IH was performed using the horseradish peroxidase (HRP) method to detect viral antigens in all examined tissues in all animals, and to identify macrophages/activated microglial cells (Iba1+), T cells (CD3+), B cells (CD45R/B220+) and neutrophils (Ly6G+) and to highlight astrocytes (glial fibrillary acidic protein, GFAP+), apoptotic cells (cleaved caspase 3+), disturbances of the fast axonal transport indicating acutely damaged neuronal axons (amyloid precursor protein, APP+) and ACE2 expression in those animals where viral antigen was detected in the brains. Antibodies and detection systems are listed in Supplemental Table S1. Briefly, after deparaffination, sections underwent antigen retrieval in citrate buffer (pH 6.0) or Tris/EDTA buffer (pH 9) for 20 min at 98 °C, followed by incubation with the primary antibodies (diluted in dilution buffer, Agilent Dako). This was followed by blocking of endogenous peroxidase (peroxidase block, Agilent Dako) for 10 min at RT and incubation with the appropriate secondary antibodies/detection systems, all in an autostainer (Dako Agilent or Ventana). Sections were subsequently counterstained with hematoxylin.

The brain of a mock-infected control hACE mouse served as normal brain control for ACE2, GFAP and APP, and a lymph node from a normal mouse for the leukocyte and apoptosis markers. Sections from the lungs served as internal positive controls for SARS-CoV-2 and IAV antigen expression, and sections incubated without the primary antibodies served as negative controls.

RNA in situ hybridization (RNA-ISH)

RNA ISH was performed using the RNAscope® ISH method (Advanced Cell Diagnostics (ACD Advanced Cell Diagnostics, Newark, California) and the RNAscope® 2.5 Detection Reagent Kit (Brown) according to the manufacturer’s protocol and as previously described (Salguero et al., 2021; Saura-Martinez et al., 2021). All cases were first tested for the suitability of the tissue (RNA preservation and quality) with an oligoprobe for Mus musculus peptidylprolyl isomerase B (PPIB) mRNA (ACD). Those yielding good PPIB signals were then subjected to RNA-ISH for nCoV2019-S (coding for Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1 complete genome; Genbank NC_045512.2). Briefly, sections were heated to 60 °C for 1 h and subsequently deparaffinized. Permeabilization was achieved by incubating the section in pretreatment solution 1 (RNAscope® Hydrogen Peroxide) for 10 min at RT, followed by boiling in RNAscope® 1X Target Retrieval Reagents solution at 100 °C for 15 min and washing in distilled water and ethanol. After digestion with RNAscope® Protease Plus for 30 min at 40 °C, sections were hybridized with the oligoprobes at 40 °C in a humidity control tray for 2 h (HybEZ™ Oven, ACD). Thereafter a serial amplification with different amplifying solutions (AMP1, AMP2, AMP3, AMP4: alternating 15 min and 30 min at 40 °C) was performed. Between each incubation step, slides were washed with washing buffer. They were subsequently incubated with AMP 5, AMP 6 and DAB at RT for 30 and 15 min respectively. Gill’s hematoxylin served to counterstain the sections which were then dehydrated with graded alcohol and xylene and coverslipped. A lung section from an infected mouse at 3 dpi served as a positive control. The negative control was consecutive sections incubated accordingly but without including the hybridization step.

Results

In K18-hACE2 mice, the later phase of SARS-CoV-2 infection is accompanied by virus spread into the central nervous system

To assess whether SARS-CoV-2 gains access to the CNS after intranasal infection with a low to medium viral dose we examined groups of K18-hACE2 mice that had been infected with a clinical isolate of SARS-CoV-2 (strain hCoV-19/England/Liverpool_REMRQ0001/2020), at 103 and 104 PFU, respectively. In addition, we examined mice that had been infected with the lower viral inoculum at day 3 post intranasal infection with 102 PFU IAV (strain A/X31). SARS-CoV-2 infected mice began to lose weight at 4 dpi and continued to lose weight until the end of the experiment, at 7 dpi. In the sequential IAV then SARS-CoV-2 infected mice, the weight loss was accelerated leading to more rapid and higher mortality, as determined by a humane endpoint of 20% weight loss (Clark et al., 2021).

At day 3 post intranasal SARS-CoV-2 infection with 103 PFU, viral antigen was detected in numerous individual and aggregates of occasionally degenerate epithelial cells in the nasal cavity in all 4 single SARS-CoV-2 infected animals and in 2 of the 4 double infected animals. Viral antigen was also found in the lungs, in both type I and II pneumocytes and, occasionally, capillary endothelial cells, in randomly distributed and variably sized patches of alveoli, with only occasional degenerate cells. This was associated with a mild increase in interstitial cellularity, endothelial cell activation with rolling, emigration and perivascular aggregation of some lymphocytes, and small macrophage aggregates, all as previously reported by this group (Clark et al., 2021). In dual infections, identical SARS-CoV-2 associated lesions were present within areas unaffected by IAV lesions. At this stage, viral antigen was detected in the olfactory epithelium in one animal, but not in brain nerves and brain including olfactory bulb. In dual infected animals, IAV antigen expression was not detected in these structures either, and there were no histological changes.

At day 7 post infection, infection of the nasal epithelium was limited; SARS-CoV-2 antigen was detected in only rare nasal epithelial cells in most mice, some were negative. As reported (Clark et al., 2021), the lungs of both single and dual infected mice showed multifocal type II pneumocyte activation and syncytial cell formation, with mild mononuclear infiltration, and mild to moderate lymphocyte-dominated vasculitis and perivascular infiltration. There were also a few focal areas of mild desquamative pneumonia with intra-alveolar macrophages/type II pneumocytes, edema and fibrin. Viral antigen expression was restricted to type I and II pneumocytes of unaltered appearing alveoli (data not shown). At this stage, viral antigen was detected in the brain of 2 of the 4 mice that had been infected with the lower dose of SARS-CoV-2 (103 PFU) alone, three of the four double infected mice, and all mice that had received the single higher dose (104 PFU) of SARS-CoV-2. IAV antigen was not detected in the brain of double infected animals. SARS-CoV-2 antigen expression in the brain was associated with its detection in the main olfactory epithelium and the olfactory bulb (Fig. 1A) in all but two animals.

Figure 1.
Figure 1.

Brain and spinal cord, K18-hACE mice, day 7 post intranasal SARS-CoV-2 infection (104 PFU as single infection or 103 PFU after initial infection with IAV (102 PFU IAV strain A/X31) as double infection). A) Double infected animal, main olfactory epithelium (MOI), cribriform plate and olfactory bulb. Viral antigen is detected in olfactory neurons and basal cells of the MOI and in granule layer, inner and outer plexiform layer, mitral layer as well as glomerular layer of the olfactory bulb. Bar = 20 μm. B) Double infected animal, examples of viral antigen expression in different brain regions. Top: frontal cortex with viral antigen expression in almost all neurons (left) and mid cortex with proportion of positive neurons (right); bar = 20 μm. Bottom: patchy virus antigen expression in the hippocampus (CA1 and CA3; left; bar = 50 μm.) and strong expression in the medulla oblongata (right; bar = 20 μm.). C) Single infected animal, medulla oblongata and cerebellum. Viral RNA is abundantly expressed in neurons in the medulla oblongata (vestibular nuclei). The cerebellar cortex exhibits a few positive Purkinje cells (see also inset). Bar = 50 μm. D) Single infected animal, thoracic spinal cord. The grey matter exhibits numerous neurons that express viral antigen (large image and bottom inset) and viral RNA (top inset) in cell body and processes. Bar = 50 μm. E, F) Double infected animal, thoracic spinal cord. There is extensive viral antigen expression in neurons in the grey matter (E). Consecutive section showing scattered apoptotic (cleaved caspase 3 positive) glial cells (F, arrowheads), among intact neurons and in the absence of an inflammatory reaction. * - central canal. Bars = 20 μm. Immunohistochemistry and RNA-ISH, hematoxylin counterstain.

In K18-hACE2 mice, SARS-CoV-2 infection in the central nervous system is restricted to neurons and spreads in the brain and into the spinal cord in a dose dependent manner

In the present study, all animals that were found to harbor viral antigen in the brain showed widespread neuronal expression, but in a dose-dependent manner. In the low dose (103 PFU) single infected animals, we only observed individual positive neurons in the olfactory bulb, but no reaction in cranial nerves or the inner ear. In contrast, in both the higher dose (104 PFU) single infected and the double infected animals, we found numerous positive neurons in the olfactory bulb (individual cells/neuronal processes in olfactory nerve layer, glomerular layer, almost all cells in external plexiform layer, individual cells in mitral cell layer), and sometimes also aggregates of positive sensory neuronal cells and their dendrites in the olfactory epithelium layer of the main olfactory epithelium (MOE; Fig. 1A). Again, no reaction was seen in cranial nerves.

In the brain, viral antigen was detected in a widespread manner across most brain regions in all animals (Fig. 1B), with less extensive viral antigen expression in the low dose single infected animals. Positive neurons were found among others in anterior olfactory nucleus, primary and secondary motor area, primary somatosensory area, anterior cingulate area, gustatory area, auditory area, infralimbic area, lateral and medial septal nucleus, caudoputamen, piriform area, visual area, ectorhinal area, entorhinal area, retrosplenial area, hippocampus and dentate gyrus, subiculum, nearly all midbrain nuclei, thalamus/hypothalamus, amygdalar nuclei, nucleus accumbens, several cranial nerve nuclei (trigeminal, vestibular, hypoglossal nuclei), reticular nucleus, cuneate nucleus, dentate nucleus. These areas are depicted in a 3D reference atlas of the Allen Mouse Brain Common Coordinate Framework (Wang et al., 2020; open access) in the following link: https://connectivity.brain-map.org/3d-viewer?v=1&types=PLY&PLY=453%2C1057%2C31%2C44%2C254%2C500%2C922%2C895%2C549%2C1097%2C386%2C370%2C1132%2C987%2C669%2C1089%2C672%2C502%2C909%2C961%2C972%2C507. Viral antigen expression was most intense in the midbrain. The cerebellum showed only individual or small groups of SARS-CoV-2 positive neurons in a few individual animals (Fig. 1C).

In the IAV and SARS-CoV-2 double infected animals as well as in the higher dose single infected animals, the virus had spread to the spinal cord where it was found in neurons in the grey matter (motor neurons and sensory neurons; Fig. 1D, E), stretching through the entire cervical and thoracic spinal cord, or decreasing progressively from the cervical spinal cord.

RNA-ISH yielded similar results as immunohistology (Fig. 1C), confirming widespread neuronal infection accentuated in the midbrain.

SARS-CoV-2 infection of the brain is associated with diffuse microglial activation and a mild macrophage and T cell dominated inflammatory response

In all animals where virus was detected in neurons in the brain, this was associated with a mild nonsuppurative (meningo)encephalitis. The inflammation was only present in areas with SARS-CoV-2-infected neurons. Therefore, it was most pronounced in frontal coronary sections of caudoputamen and the thalamus/hypothalamus region as well as in the hippocampal area and was represented by infiltration of the wall and the perivascular space of small veins by predominantly mononuclear cells, accompanied by a mild increase in parenchymal cellularity (Fig. 2A). The majority of cells in the (peri)vascular infiltrates were Iba1-positive macrophages (Fig. 2B). These were accompanied by T cells (CD3+) which comprised up to approximately 30% of the perivascular cells (Fig. 2C). Individual T cells were also found in the neuroparenchyma, mostly in proximity to perivascular infiltrates (Fig. 2C). The vascular infiltrates contained rare individual neutrophils (Ly6G+) and B cells (CD45R/B220+) (Fig. 2D). The inflammatory infiltrates were accompanied by moderate diffuse microglial activation/microgliosis in areas with SARS-CoV-2 infected neurons (Figs. 2B, E and 3A, B). Microglial nodules were detected mainly adjacent to areas with perivascular infiltrates (Fig. 2E).

Figure 2.
Figure 2.

Brain, K18-hACE mouse, day 7 post intranasal SARS-CoV-2 infection (104 PFU) after initial infection with IAV (102 PFU IAV strain A/X31). A) Brain stem with moderate (peri)vascular leukocyte infiltration and mildly increased cellularity in the parenchyma. HE stain. B) Macrophages (Iba1+) dominate in the (peri)vascular infiltrate (inset: arrowheads) and the surrounding parenchyma exhibits microglial activation (Iba1+ stellate shaped cells). C) T cells (CD3+) are also abundant in the (peri)vascular infiltrates and are found infiltrating the adjacent parenchyma. Inset: vessel with infiltrating T cells; some are degenerate (arrowheads). D) Neutrophils (Ly6G+; top, arrowhead) and B cells (CD45R/B220+; bottom, arrowheads) are very rare in the infiltrates. E. Brain stem with activated microglial cells (Iba1+) and small microglial nodule (arrow). F. Staining of astrocytes (GFAP+) shows hypertrophied astrocytes around a vessel with a mild perivascular infiltrate. B-F: immunohistochemistry, hematoxylin counterstain. Bars = 20 μm.

Figure 3.
Figure 3.

Brain, K18-hACE mice, mock infected and at day 7 post intranasal SARS-CoV-2 infection (103 PFU) after initial infection with IAV (102 PFU IAV strain A/X31). A) Mock infected mouse. Quiescent microglia (Iba1+). B) Infected animal. Diffuse microglial activation (Iba1+ stellate cells). C) Mock infected mouse. Endothelial cells show cytoplasmic ACE2 expression. D-F) Infected animal. D) Vessel with moderate leukocyte infiltration with focal destruction of the vessel wall (arrows) and some degenerate leukocytes (leukocytoclastic component). Top: HE stain; bottom: staining for ACE2, showing disruption of the endothelial cells layer. E) Vessel with moderate leukocyte infiltration (top: HE stain; bottom: staining for cleaved caspase 3). Individual cells in the infiltrate and in the adjacent parenchyma (top and bottom left: arrowheads) and endothelial cells in an affected vessel (bottom right: arrowhead) undergo apoptosis. F) Activated microglia (Iba1+; left). Staining for cleaved caspase 3 (right) shows apoptosis of a microglial cell (arrow) and of small round cells (arrowheads; morphology consistent with lymphocytes). A-E: bars =20 μm; F: bars = 10 μm.

The double infected animals also showed a mild lympho-histiocytic meningitis (Clark et al., 2021), more pronounced in caudoputamen, thalamic and hypothalamic regions compared to single infected animals.

There was no evidence of prominent astrogliosis (Fig. 2F). However, astrocytes immediately adjacent to perivascular infiltrates showed hypertrophy of the cytoplasm consistent with activation.

There is no evidence of viral infection of glial cells, endothelial cells or leukocytes or of neuronal cell death, axonal damage or demyelination in association with SARS-CoV-2 infection, but of apoptotic death of endothelial cells and immune cells

Despite widespread infection of neurons, there was no morphological evidence of neuronal cell death. Staining for cleaved caspase 3 did not mark any neurons. Also, staining for amyloid precursor protein (APP) to detect disturbances in fast axonal transport as an indicator of acute axonal damage did not show any evidence of the latter. Furthermore, there were no changes indicating demyelination of the white matter. Capillary endothelial cells which are positive for ACE2 throughout the brain and spinal cord (Fig. 3C) were negative in both SARS-CoV-2 IHC and ISH. However, in some vessels that exhibited a leukocyte infiltrate, the endothelial layer appeared focally discontinuous (Fig. 3D), confirming vasculitis. The infiltrate contained scattered degenerate cells suggesting a leukocytoclastic component. (Fig. 3D, E). This was confirmed by staining for cleaved caspase 3; both endothelial cells and leukocytes in the vascular infiltrates were found to be apoptotic. Apoptosis (cleaved caspase 3+) was also observed in a few leukocytes (morphology consistent with lymphocytes) in the adjacent parenchyma (likely infiltrating T cells) (Fig. 3E) and in occasional microglial cells (Fig. 3F). In none of the brains was there any evidence of SARS-CoV-2 antigen or RNA expression in glial cells.

Discussion

COVID-19 is primarily a respiratory disease, with potentially fatal systemic complications that can also involve the CNS. At present, the pathogenetic and clinical role of encephalopathy in COVID-19 patients is controversely discussed. A variety of mild and/or severe clincal signs have been described, and the reported morphological findings in the brain differ between studies; similarly, the presence and distribution of viral RNA or antigen appears to be inconsistent. Many questions are currently still open regarding the infectious route and spatio-temporal distribution of SARS-CoV-2 in the CNS of COVID-19 patients without comorbitidies, showing the need for appropriate animal models.

In this context, the hACE2 transgenic mouse under the control of the human cytokeratin 18 promoter, a commonly used mouse model to study pathogenetic effects of SARS-CoV-2 infection, has been employed not only in the present, but also in several other recent studies using the USA-WA1 strain, predominantly at high doses (105 to 1.5 x 106 PFU) (Oladunni et al., 2020; Carossino et al., 2021; Kumari et al., 2021, Song et al., 2021; Yinda et al., 2021; Zheng et al., 2021). All these studies show that intranasal inoculation of K18-hACE2 mice can lead to infection and extensive virus spread in the brain within 6 or 7 days. Infection even stretches into the spinal cord and can basically affect the entire grey matter, including, though only rarely, also the cerebellar cortex (Purkinje cells). This indicates that SARS-CoV-2 has no selective neurotropism.

In the present study, intranasala inoculation of mice with a low viral dose (103 PFU of the hCoV-2/human/Liverpool/REMRQ0001/2020) resulted in limited CNS infection; it was most pronounced in basal structures of the brain and did not reach the spinal cord. With the higher infectious dose (104 PFU) or with IAV pre-infection, we observed widespread extensive viral antigen expression and involvement of the spinal cord. This suggests some dose dependence of virus spread in the CNS, as it was suspected in another study (Yinda et al., 2021), and an effect of prior damage in the respiratory tract (Clark et al., 2021). At the same time, we and others found virus in the olfactory epithelium and in neurons in the olfactory bulb (Carossino et al., 2021; Kumari et al., 2021). Therefore, a rostral to caudal spread of infection with emphasis on basal structures and consequent infection of cortical areas is most likely. This implies a direct neuronal spread of the virus rather than a disseminated pattern which would be consistent with a hematogenous route of infection. A recent ultrastructural examination on SARS-CoV-2 infected human brain organoids is in agreement with these observations, as it provides evidence of virus cell-to-cell-spread beween neurons in the organoids (Song et al., 2021). Many of the SARS-CoV-2 antigen positive neurons of mice of this study are located in areas which are secondary or tertiary connections of the olfactory bulb. This gives further evidence of virus entry via the olfactory bulb, as confirmed in both mice (Carossino et al., 2021; Zheng et al., 2021) and humans (Meinhard et al., 2020) as a natural route of brain infection by SARS-CoV-2. However, many virus-positive regions that are not directly connected to the olfactory system were also identified, providing further evidence of an additional route of viral dissemination (Zheng et al., 2021).

Clinical signs consistent with neurological disease have only been reported in one experimental study to date, where mice had shown hunchbacked posture, ruffled fur, tremors and ataxic gait from day 4 pi, and died after day 6. These mice carried very high levels of infectious virus in the brain and showed an encephalitis with perivascular hemorrhage. Neuronal death via apoptosis was suspected (Kumari et al., 2021). Other studies reported perivascular cuffs or vasculitis, neuronal degeneration and necrosis, satellitosis, parenchymal edema, and occasional microthrombi (Oladunni et al., 2020; Carossino et al., 2021; Yinda et al., 2021; Zheng et al., 2021), all at day 7 post infection. The present study confirms that SARS-CoV-2 readily infects neurons in the K18-hACE2 mice, with viral protein accumulation in the entire cytoplasm including the cell processes, but does not provide evidence of neuronal cell death in association with infection, indicating that SARS-CoV-2 has no direct cytopathic effect on neurons. This may be due to the lower viral dose, provided that a high viral load would damage neurons directly.

Involvement of the spinal cord, which was a prominent feature in our mouse model, has only been reported in a few human cases (Mondal et al., 2020). It might be a so far under-recognized neurological complication, since neuropathological assessments did not go beyond neuroimaging and evaluation of several CSF parameters.

Similar to Carossino et al. (2021), the present study did not find evidence of demyelination. Furthermore, axonal damage was not present in the investigated murine brain sections. However, while both axonal damage and demyelination can occur in COVID-19 patients, they are apparently not common neuropathological findings (Kantonen et al., 2020; Reichard et al., 2020; Salomon et al., 2020).

Neuronal SARS-CoV-2 infection without obvious neuronal degeneration is reminiscent of other neurotropic and persistent viral infections, like herpes simplex virus (HSV). HSV-1 establishes latency in the mouse model within the earliest stages of acute infection, with the viral genome reaching the neuronal ganglia within the first 24 hours of infection (Steiner et al., 1990). Further studies would now be required to determine whether SARS-CoV-2 also establishes latency or whether there is subsequent neuronal damage.

Viral infection of neurons is evidently associated with an antiviral response in the mice, as indicated by a reported increase in IFN-α mRNA in the brain from day 5 pi onwards, with a peak of both mRNA and protein on day 6 (Kumari et al., 2021). This is accompanied by an inflammatory response in the brain parenchyma. Similar to a previous study (Oladunni et al., 2020), we observed a mild non-suppurative, macrophage and T cell driven encephalitis (perivascular infiltrates and occasional vasculitis) in all mice that harbored viral antigen in the brains at 7 dpi. This appeared to be slightly more intense with more extensive neuronal virus antigen expression in animals that had received the higher viral dose (104 PFU) or had been preinfected with IAV, suggesting some dependence on the infectious dose or easier access to the brain with pre-existing damage due to IAV infection (Clark et al., 2021; Yinda et al., 2021). Transcriptional investigations also confirmed the inflammatory state of the brain, demonstrating an increase in infammatory cytokines and chemokines (IL-6, TNF-α, IFN-γ, IL-1β, MIP-1α.MIP-2, IP-10) in the brain of infected mice (Oladunni et al., 2020; Kumari et al., 2021). This might also explain the activation/hypertrophy of astrocytes in areas with perivascular infiltrates and the diffuse microglial activation and multifocal microgliosis that we and others observed (Winkler et al., 2020; Carossino et al., 2021; Yinda et al., 2021). Both glial cell populations are responsive to proinflammatory signals from endothelial cells, macrophages and/or neurons (Murta et al., 2020). The proinflammatory gene expression program initiated after viral infection would expand neuroinflammation (Murta et al., 2020). Activated microglia may itself undergo a phenotypic shift and display exaggerated release of pro-inflammatory mediators and aberrant phagocytic activity, inducing neurodegeneration (Tremblay et al., 2020). This could explain the diffuse astrogliosis reported from other mouse and human studies (Carossino et al., 2021; Matschke et al., 2020) as well as neuronophagia by microglial cells which was seen in some human COVID-19 patients (Al-Dalahmah et al., 2020) and one mouse study (Carossino et al., 2021).

In previous studies we and others have shown that IAV pre-infection of hACE2 mice results in more severe SARS-CoV-2 associated pulmonary changes and higher amounts of infectious virus at 6 or 7 days post SARS-CoV-2 infection (Bai et al., 2021; Clark et al., 2021). Interestingly though, viral loads in the brain were not found to be increased (Bai et al., 2021), although we observed higher frequency and more widespread brain infection after the lower SARS-CoV-2 dose in animals that were infected with IAV. Also, the inflammatory response was slightly more intense in these animals. It is currently unclear which direct impact IAV infection has for the subsequent SARS-CoV-2 challenge, but more efficient virus entry could be an option, since IAV infection was shown to upregulate ACE2 expression in vitro (Bai et al., 2021).

While we did not find evidence of neuronal death, we observed apoptosis of infiltrating lymphocytes, capillary endothelial cells and macrophages/microglial cells in proximity to perivascular infiltrates. As in a previous study (Carossino et al., 2021), none of these cells were found to be SARS-CoV-2 infected. This result is in line with recent findings in SARS-CoV-2 infected human brain organoids which provided evidence that infected neurons do not die but can promote the death of adjacent uninfected cells (Song et al., 2021). Using single cell RNA sequencing, the study showed that SARS-CoV-2 infected cells in the organoids were in a hypermetabolic state, whereas uninfected cells nearby were in a catabolic state and a hypoxic environment, as shown by HIF1α expression (Song et al., 2021). The same may be true for the brain of K18-hACE2 mice with widespread neuronal SARS-CoV-2 infection. Also, coupled proliferation and apoptosis are assumed to maintain the quite rapid turnover of microglia in the adult brain (Askew et al., 2017). We did not determine the proliferation rate in this study, but such “physiological” turnover should be considered when interpreting microglial apoptosis in SARS-CoV-2 infected mice.

Several morphological changes in the mice used in the present study recapitulate findings reported in brains of human COVID-19 patients, like mild perivascular inflammatory infiltrates (Solomon et al., 2020) and microgliosis (Schuhrink et al., 2020). In the mice, the inflammatory processes were only mild and more pronounced in frontal regions like caudoputamen and the thalamus/hypothalamus region as well as the hippocampal area. Further vascular lesions apart from vasculitis/endotheliitis, like ischemic infarcts (Kantonen et al., 2020; Song et al., 2021) or microthrombi (Fabbri et al., 2020) that seem to be frequent in fatal human COVID-19 cases, are obviously not a regular feature in this mouse model, since only two studies reported occasional microthrombi in the brain (Yinda et al., 2021; Zheng et al., 2021). This could be due to the lack of endothelial cell infection in the brain of the mice, whereas it was seen in association with fresh ischemic infarcts in the brain of a COVID-19 patient (Meinhardt et al., 2021; Song et al., 2021). Interestingly, the presence of virus in the brain of the human patients is apparently not consistently associated with leukocyte infiltration, indicating that SARS-CoV-2 does not necessarily induce an immune response like other neurotropic viruses (Song et al., 2021).

The main host receptor for SARS-CoV-2 is the human angiotensin-converting enzyme 2 (hACE2). While a study in the brain of fatal human COVID-19 cases showed ACE2 expression in cortical neurons and found evidence that ACE2 is required for infection of human brain organoids (Song et al., 2021), neuroinvasion and spread in the K18-hACE2 mice is apparently not directly dependent upon ACE2 expression, because the virus does not infect all ACE2 expressing cells and does infect cells without apparent ACE2 expression (Carossino et al., 2021). Indeed, in line with the findings of previous studies we only detected ACE2 protein expression in capillary endothelial cells, ependymal cells and choroid plexus epithelium in the brain and spinal cord, in the absence of detectable viral antigen (Carossini et al., 2021; Clark et al., 2021; Song et al., 2021). In human COVID-19 patients, the endothelium of capillaries in kidney, liver, heart, lung and small intestine was shown to become infected, and this was associated with an endotheliitis (Varga et al., 2020). Furthermore, ultrastructural examination of the brain of one human patient found viral particles in small vesicles of endothelial cells, suspecting an additional hematogenous route of brain infection (Paniz-Mondolfi et al., 2020). Indeed, using intravenously injected radioiodinated SARS-CoV-2 S1 it has been shown that the viral protein can cross the BBB, and likely by absorptive transcytosis (Rhea et al., 2020). It may hence be due to the fact that endothelial ACE2 expression in the K18-hACE2 mice represents only the murine protein (Carassino et al., 2021) that the brain endothelium of the mice does not become infected by SARS-CoV-2. Based on current knowledge, it seems likely that in COVID-19 patients the virus can access the brain in several ways. In severe COVID-19, viremia could allow access to the brain via the vasculature (Colagrossi et al., 2021). With the platelet hyperactivity in critically ill patients (Comer et al., 2021) and abnormal blood clotting or unusual thrombotic presentations (Helms et al., 2020b, Klok et al., 2020) this might lead to the ischemic changes described in a proportion of fatal cases, without viral infection of neurons. This might not be mirrored by the murine model as viremia may not occur (Yinda et al., 2021). In mild COVID-19, i.e. without viremia, infection of the brain via the olfactory bulb and possible other neurogenic routes could occur. This would then lead to exclusive neuronal infection and an only mild inflammatory response. It might be this scenario that explains the loss of taste and smell and severe headaches reported in patients with mild disease.

The murine model does not fulfil all morphological criteria of acute human neurological COVID-19. However, brain infection following a lower dose of intranasal challenge might represent a mouse model for chronic/long COVID-19 studies. The pathogenesis of this sequel of the acute disease is still unknown, but fatigue, muscle aches, breathlessness, and headaches are the most frequently reported symptoms (Dennis et al., 2020; Brodin, 2021). A persistent low-grade smoldering inflammatory response to newly budding virions might be central to the condition. Also, degeneration or impaired function of neuronal and glial cells that are cardinal for the physiological function of the brain might be an option (Baig, 2020). A mild inadequate immune response with persistent viral load and viral evasion of the immune surveillance are suspected key factors (Baig, 2020). This is supported by the fact that COVID-19 patients still exhibit a significant remaining inflammatory response in the serum at 40-60 days post infection (Doykov et al., 2020). Further investigations of the inflammatory response at transcriptome and translational level in the murine model could provide further insights.

These data also have important implications for the development of therapeutic interventions. Firstly, the endothelium and astrocyte foot processes represent key components of the BBB, protecting the brain from accumulation of endo- and xeno-biotics. Future studies should address the consequences of infection for maintenance of barrier integrity to mitigate potential inadvertant delivery of neurotoxic agents that wouldn’t otherwise permeate the brain. Secondly, several studies have already sought to understand pulmonary distribution of postulated therapeutic interventions (Arshad et al., 2020; Hanafin et al., 2021; Rajoli et al., 2021) but robust efficacy of antivirals and/or immunomodulatory agents may also necessitate adequate exposure within the CNS. Notably, the repurposed antivirals remdesivir, favipiravir and molnupiravir exhibit low concentrations in the brain relative to plasma in preclinical species (Bocan et al., 2019; Painter et al., 2019; EMA, 2020; Jorgensen et al., 2020). Furthermore, dexamethasone also exhibits low brain penetration in mice with an intact BBB, but this increases in mice genetically engineered to be absent a critical drug transporter, P-glycoprotein (Meijer et al., 1998). Further work is required to define the importance of brain penetration of therapeutics being investigated as interventions across the spectrum of disease from prevention, mild, moderate, severe to long COVID-19.

Conclusions

Despite widespread neuronal infection, pathomorphological changes of the course of disease consisted of mild lymphohistiocytic inflammation and microglial activation. Solely neuronal cells were infected which supported the infectious route via the olfactory epithelium, olfacory bulb and transsynaptic spreading. The limited expression of ACE2 raises the question for ACE2-independent pathogenetic mechanisms to explain the neurotropism of the virus. Microgliosis and immune cell apoptosis were main pathological features in our study indicating a potential important role of microglial cells in the pathogenesis of neuromanifestation in COVID-19.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

Acknowledgements

We are grateful to the technical staff in the Histology Laboratory, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich (IVPZ), for excellent technical support. This work was funded in part by the US Food and Drug Administration (USA) 75F40120C00085, Characterization of severe coronavirus infection in humans and model systems for medical countermeasure development and evaluation (JAH). Work in the lab is also supported by MRC grant MR/W005611/1, G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation (JPS and JAH).

Footnotes

  • * Authors’ Email addresses: Frauke Seehusen: frauke.seehusen{at}uzh.ch, Jordan J Clark: Jordan.Clark{at}liverpool.ac.uk, Parul Sharma: Parul.Sharma{at}liverpool.ac.uk, Krishanthi Subramaniam: K.Subramaniam{at}liverpool.ac.uk, Sabina Wunderlin Giuliani: sabina.wunderlin{at}vetpath.uh.ch, Grant L Hughes: grant.hughes{at}lstmed.ac.uk, Edward I Patterson: ian.patterson{at}lstmed.ac.uk, Benedict D Michael: Benedict.Michael{at}liverpool.ac.uk, Andrew Owen: aowen{at}liverpool.ac.uk, Julian A Hiscox: Julian.Hiscox{at}liverpool.ac.uk, James Stewart: J.P.Stewart{at}liverpool.ac.uk, Anja Kipar: anja.kipar{at}uzh.ch, akipar{at}liverpool.ac.uk

REFERENCES

  1. ↵
    Alam SB, Willows S, Kulka M, Sandhu JK, 2020. Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system. Eur J Neurol 27(11):2348–2360. doi: 10.1111/ene.14442.
    OpenUrlCrossRef
  2. ↵
    Al-Dalahmah O, Thakur KT, Nordvig AS, Prust ML, Roth W, Lignelli A, Uhlemann AC, Miller EH, Kunnath-Velayudhan S, Del Portillo A, Liu Y, Hargus G, Teich AF, Hickman RA, Tanji K, Goldman JE, Faust PL, Canoll P, 2020. Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage. Acta Neuropathol Commun 8(1):147. doi: 10.1186/s40478-020-01024-2.
    OpenUrlCrossRef
  3. ↵
    Al-Sarraj S, Troakes C, Hanley B, Osborn M, Richardson MP, Hotopf M, Bullmore E, Everall IP, 2021. Invited Review: The spectrum of neuropathology in COVID-19. Neuropathol Appl Neurobiol 47(1):3–16. doi: 10.1111/nan.12667.
    OpenUrlCrossRefPubMed
  4. Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O’Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A, 2021. Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther 108(4):775–790. doi: 10.1002/cpt.1909.
    OpenUrlCrossRef
  5. ↵
    Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, Chapman MA, Riecken K, Beccari S, Sierra A, Molnár Z, Cragg MS, Garaschuk O, Perry VH, Gomez-Nicola D, 2017. Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain. Cell Rep. 18(2):391–405. doi: 10.1016/j.celrep.2016.12.041.
    OpenUrlCrossRefPubMed
  6. ↵
    Bai L, Zhao Y, Dong J, Liang S, Guo M, Liu X, Wang X, Huang Z, Sun X, Zhang Z, Dong L, Liu Q, Zheng Y, Niu D, Xiang M, Song K, Ye J, Zheng W, Tang Z, Tang M, Zhou Y, Shen C, Dai M, Zhou L, Chen Y, Yan H, Lan, K Xu, K, 2021. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res 1–9. doi: 10.1038/s41422-021-00473-1.
    OpenUrlCrossRef
  7. ↵
    Baig AM, 2020. Deleterious outcomes in long-hauler COVID-19: The effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci 11(24):4017–4020. doi: 10.1021/acschemneuro.0c00725.
    OpenUrlCrossRef
  8. ↵
    Bocan TM, Basuli F, Stafford RG, Brown JL, Zhang X, Duplantier AJ, Swenson RE, 2019. Synthesis of [18F]Favipiravir and biodistribution in C3H/HeN Mice as assessed by positron emission tomography. Sci Rep 9(1):1785. doi: 10.1038/s41598-018-37866-z.
    OpenUrlCrossRef
  9. ↵
    Brodin P, 2021. Immune determinants of COVID-19 disease presentation and severity. Nat Med 27, 28–33. doi: 10.1038/s41591-020-01202-8.
    OpenUrlCrossRefPubMed
  10. ↵
    Bussani R, Schneider E, Zentilin L, Collesi C, Ali H, Braga L, Volpe MC, Colliva A, Zanconati F, Berlot G, Silvestri F, Zacchigna S, Giacca M, 2020. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine 61:103104. doi: 10.1016/j.ebiom.2020.103104.
    OpenUrlCrossRef
  11. ↵
    Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, Smura T, Levanov L, Szirovicza L, Tobi A, Kallio-Kokko H, Österlund P, Joensuu M, Meunier FA, Butcher SJ, Winkler MS, Mollenhauer B, Helenius A, Gokce O, Teesalu T, Hepojoki J, Vapalahti O, Stadelmann C, Balistreri G, Simons M, 2020. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370(6518):856–860. doi: 10.1126/science.abd2985.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Carossino M, Montanaro P, O’Connell A, Kenney D, Gertje H, Grosz KA, Kurnick SA, Bosmann M, Saeed M, Balasuriya UBR, Douam F, Crossland NA, 2021. Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice is partially dependent on hACE2 expression. bioRxiv preprint doi: doi.org/10.1101/2021.01.13.425144. version posted January 15, 2021.
  13. ↵
    Clark JJ, Penrice-Randal R, Sharma P, Kipar A, Dong X, Davidson A, Kavanagh Williamson M, Matthews DA, Turtle L, Prince T, Hughes GL, Patterson EI, Shawli G, Subramaniam K, Sharp J, McLaughlin L, Zhou E-M, Turner JD, Marriott AE, Colombo S, Pennington SH, Biagini G, Owen A, Hiscox JA, Stewart JP, 2021. Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19. bioRxiv preprint doi: 10.1101/2020.10.13.334532.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Colagrossi L, Antonello M, Renica S, Merli M, Matarazzo E, Travi G, Vecchi M, Colombo J, Muscatello A, Grasselli G, Molteni SN, Scaravilli V, Cattaneo E, Fanti D, Vismara C, Bandera A, Gori A, Puoti M, Cento V, Alteri C, Perno CF, 2021. SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. BMC Infect Dis 21(1):184. doi: 10.1186/s12879-021-05886-2.
    OpenUrlCrossRef
  15. ↵
    Comer SP, Cullivan S, Szklanna PB, Weiss L, Cullen S, Kelliher S, Smolenski A, Murphy C, Altaie H, Curran J, O’Reilly K, Cotter AG, Marsh B, Gaine S, Mallon P, McCullagh B, Moran N, Ní Áinle F, Kevane B, Maguire PB, COCOON study investigators, 2021. COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biol 19(2):e3001109. doi: 10.1371/journal.pbio.3001109.
    OpenUrlCrossRef
  16. ↵
    Deigendesch N, Sironi L, Kutza M, Wischnewski S, Fuchs V, Hench J, Frank A, Nienhold R, Mertz KD, Cathomas G, Matter MS, Siegemund M, Tolnay M, Schirmer L, Pröbstel AK, Tzankov A, Frank S. Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology, 2020. Acta Neuropathol 140(4):583–586. doi: 10.1007/s00401-020-02213-y.
    OpenUrlCrossRef
  17. ↵
    Dennis A, Wamil M, Kapur S, Alberts J, Badley AD, Decker GA, Rizza SA, Banerjee R, Banerjee A, 2020. Multi-organ impairment in low-risk individuals with long COVID. medRxiv 2020.10.14.20212555. doi: 10.1101/2020.10.14.20212555
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Doykov I, Hällqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE, 2020. ‘The long tail of Covid-19’ - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res 9:1349. doi: 10.12688/f1000research.27287.2. PMID: 33391730; PMCID: PMC7745182.
    OpenUrlCrossRefPubMed
  19. ↵
    EMA (European Medicines Agency), 2020. Remdesivir Gilead – Summary on compassionate use. EMA/178637/2020
  20. ↵
    Fabbri VP, Foschini MP, Lazzarotto T, Gabrielli L, Cenacchi G, Gallo C, Aspide R, Frascaroli G, Cortelli P, Riefolo M, Giannini C, D’Errico A, 2021. Brain ischemic injury in COVID-19-infected patients: a series of 10 post-mortem cases. Brain Pathol 31(1):205–210. doi: 10.1111/bpa.12901.
    OpenUrlCrossRef
  21. Golden JW, Cline CR, Zeng X, Garrison AR, Carey BD, Mucker EM, White LE, Shamblin JD, Brocato RL, Liu J, Babka AM, Rauch HB, Smith JM, Hollidge BS, Fitzpatrick C, Badger CV, Hooper JW, 2020. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight 5(19):e142032. doi: 10.1172/jci.insight.142032.
    OpenUrlCrossRef
  22. ↵
    Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anheim M, Meziani F, 2020a. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382(23):2268–2270. doi: 10.1056/NEJMc2008597.
    OpenUrlCrossRefPubMed
  23. ↵
    Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L, Anglés-Cano E, Sattler L, Mertes PM, Meziani F; CRICS TRIGGERSEP Group, 2020b. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46(6):1089–1098. doi: 10.1007/s00134-020-06062-x.
    OpenUrlCrossRefPubMed
  24. ↵
    Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S, 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280 e278. doi: 10.1016/j.cell.2020.02.052
    OpenUrlCrossRefPubMed
  25. ↵
    Huang YH, Jiang D, Huang JT, 2020. SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis. Brain Behav Immun 87:149. doi: 10.1016/j.bbi.2020.05.012.
    OpenUrlCrossRef
  26. ↵
    Jaunmuktane Z, Mahadeva U, Green A, Sekhawat V, Barrett NA, Childs L, Shankar-Hari M, Thom M, Jäger HR, Brandner S, 2020. Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19. Acta Neuropathol 140(3):397–400. doi: 10.1007/s00401-020-02190-2.
    OpenUrlCrossRef
  27. ↵
    Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: Review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19, 2020. Pharmacotherapy 40(7):659–671. doi: 10.1002/phar.2429.
    OpenUrlCrossRefPubMed
  28. ↵
    Kantonen J, Mahzabin S, Mäyränpää MI, Tynninen O, Paetau A, Andersson N, Sajantila A, Vapalahti O, Carpén O, Kekäläinen E, Kantele A, Myllykangas L. Neuropathologic features of four autopsied COVID-19 patients, 2020. Brain Pathol 30(6):1012–1016. doi: 10.1111/bpa.12889.
    OpenUrlCrossRef
  29. ↵
    Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H, 2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 191:148–150. doi: 10.1016/j.thromres.2020.04.041.
    OpenUrlCrossRefPubMed
  30. ↵
    Kumari P, Rothan HA, Natekar JP, Stone S, Pathak H, Strate PG, Arora K, Brinton MA, Kumar M, 2021. Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice. Viruses 13:132. doi: 10.3390/v13010132.
    OpenUrlCrossRef
  31. ↵
    Lavi E, Cong L, 2020. Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection. Exp Mol Pathol 115:104474. doi: 10.1016/j.yexmp.2020.104474.
    OpenUrlCrossRef
  32. Mahalaxmi I, Kaavya J, Mohana Devi S, Balachandar V, 2021. COVID-19 and olfactory dysfunction: A possible associative approach towards neurodegenerative diseases. J Cell Physiol 236(2):763–770. doi: 10.1002/jcp.29937.
    OpenUrlCrossRef
  33. ↵
    Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B, 2020. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 77(6):683–690. doi: 10.1001/jamaneurol.2020.1127.
    OpenUrlCrossRefPubMed
  34. ↵
    Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M, Dottermusch M, Heinemann A, Pfefferle S, Schwabenland M, Sumner Magruder D, Bonn S, Prinz M, Gerloff C, Püschel K, Krasemann S, Aepfelbacher M, Glatzel M. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series, 2020. Lancet Neurol 19(11):919–929. doi: 10.1016/S1474-4422(20)30308-2.
    OpenUrlCrossRefPubMed
  35. ↵
    McCray PB Jr., Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Netland J, Jia HP, Halabi C, Sigmund CD, Meyerholz DK, Kirby P, Look DC, Perlman S, 2007. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol 81:813–821. doi:10.1128/JVI.02012-06.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Meijer OC, de Lange ECM, Breimer DD, de Boer AG, Workel JO, de Kloet ER, 1998. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139(4):1789–1793. doi: 10.1210/endo.139.4.5917.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brünink S, Greuel S, Lehmann M, Hassan O, Aschman T, Schumann E, Chua RL, Conrad C, Eils R, Stenzel W, Windgassen M, Rößler L, Goebel HH, Gelderblom HR, Martin H, Nitsche A, Schulz-Schaeffer WJ, Hakroush S, Winkler MS, Tampe B, Scheibe F, Körtvélyessy P, Reinhold D, Siegmund B, Kühl AA, Elezkurtaj S, Horst D, Oesterhelweg L, Tsokos M, Ingold-Heppner B, Stadelmann C, Drosten C, Corman VM, Radbruch H, Heppner FL, 2021. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 24: 168–175 doi: 10.1038/s41593-020-00758-5.
    OpenUrlCrossRefPubMed
  38. ↵
    Michael BD, Bricio-Moreno L, Sorensen EW, Miyabe Y, Lian J, Solomon T, Kurt-Jones EA, Luster AD, 2020. Astrocyte- and neuron-derived CXCL1 drives neutrophil transmigration and blood-brain barrier permeability in viral encephalitis. Cell Rep. 2020 September 15; 32(11): 108150. doi:10.1016/j.celrep.2020.108150
    OpenUrlCrossRef
  39. ↵
    Mondal R, Deb S, Shome G, Ganguly U, Lahiri D, Leon JB, 2020. Spectrum of spinal cord involvement in COVID-19: A systematic review. medRxiv 2020.09.29.20203554. doi: 10.1101/2020.09.29.20203554.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, Nakao A, Takeda M, Haro H, Inoue O, Suzuki-Inoue K, Kubokawa K, Ogihara S, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Sasaki Y, Enomoto N, Ishihara H, Furuya S, Yamamoto T, Shimada S, 2020. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 94:55–58. doi: 10.1016/j.ijid.2020.03.062.
    OpenUrlCrossRefPubMed
  41. ↵
    Murta V, Farías MI, Pitossi FJ, Ferrari CC, 2015. Chronic systemic IL-1β exacerbates central neuroinflammation independently of the blood-brain barrier integrity. J Neuroimmunol 278:30–43. doi: 10.1016/j.jneuroim.2014.11.023.
    OpenUrlCrossRef
  42. ↵
    Murta V, Ferrari C, 2016. Peripheral inflammation and demyelinating diseases. Adv Exp Med Biol 949:263–285. doi: 10.1007/978-3-319-40764-7_13.
    OpenUrlCrossRef
  43. ↵
    Murta V, Villarreal A, Ramos AJ, 2020. Severe Acute Respiratory Syndrome Coronavirus 2 impact on the central nervous system: Are astrocytes and microglia main players or merely bystanders? ASN Neuro 12:1759091420954960. doi: 10.1177/1759091420954960.
    OpenUrlCrossRef
  44. ↵
    Najjar, S Najjar A, Chong DJ, Pramanik BK, Kirsch C, Kuzniecky RI, Pacia SV, Azhar S, 2020. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation 17: 231. doi: 10.1186/s12974-020-01896-0.
    OpenUrlCrossRef
  45. ↵
    Oladunni FS, Park J-G, Pino PA, Gonzalez O, Akhter A, Allué-Guardia A, Olmo-Fontánez A, Gautam S, Garcia-Vilanova A, Ye C, Chiem K, Headley C, Dwivedi V, Parodi LM, Alfson KJ, Staples HM, Schami A, Garcia JI, Whigham A, Platt RN, Gazi M, Martinez J, Chuba C, Earley S, Rodriguez OH, Davis Mdaki S, Kavelish KN, Escalona R, Hallam CRA, Christie C, Patterson JL, Anderson TJC, Carrion R, Dick EJ, Hall-Ursone S, Schlesinger LS, Alvarez X, Kaushal D, Giavedoni LD, Turner J, Martinez-Sobrido L, Torrelles JB, 2020. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun 11(1):6122. doi: 10.1038/s41467-020-19891-7.
    OpenUrlCrossRef
  46. ↵
    Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger KA, Skliut M, Weinberger J, Dangayach NS, Bederson JB, Tuhrim S, Fifi JT, 2020. Large-vessel stroke as a presenting feature of COVID-19 in the young. N Engl J Med 382(20):e60. doi: 10.1056/NEJMc2009787.
    OpenUrlCrossRefPubMed
  47. ↵
    George R. Painter, Richard A. Bowen, Gregory R. Bluemling, John DeBergh, Vindhya Edpuganti, Prabhakar R. Gruddanti, David B. Guthrie, Michael Hager, Damien L. Kuiper, Mark A. Lockwood, Deborah G. Mitchell, Michael G. Natchus, Zachary M. Sticher, Alexander A. Kolykhalov. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Research, Volume 171, 2019, 104597, doi: 10.1016/j.antiviral.2019.104597.
    OpenUrlCrossRef
  48. ↵
    Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M, 2020. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 92(7):699–702. doi: 10.1002/jmv.25915.
    OpenUrlCrossRefPubMed
  49. ↵
    Patterson EI, Prince T, Anderson ER, Casas-Sanchez A, Smith SL, Cansado-Utrilla C, Solomon T, Griffiths MJ, Acosta-Serrano Á, Turtle L, Hughes G, 2020. Methods of inactivation of SARS-CoV-2 for downstream biological assays. J Infect Dis 222(9):1462–1467. doi:10.1093/infdis/jiaa507.
    OpenUrlCrossRefPubMed
  50. ↵
    Perry VH, Cunningham C, Holmes C, 2007. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7(2):161–7. doi: 10.1038/nri2015.
    OpenUrlCrossRefPubMedWeb of Science
  51. Perry VH, Teeling J, 2013. Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol 35(5):601–12. doi: 10.1007/s00281-013-0382-8.
    OpenUrlCrossRefPubMed
  52. ↵
    Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B, 2020. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: Imaging features. Radiology 296(2):E119–E120. doi: 10.1148/radiol.2020201187.
    OpenUrlCrossRefPubMed
  53. ↵
    Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Pueschel K, Aepfelbacher M, Huber TB, 2020. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 383(6):590–592. doi: 10.1056/NEJMc2011400.
    OpenUrlCrossRefPubMed
  54. ↵
    Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyoussi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O’Neill PM, Hong WD, Biagini GA, Owen A. Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis, 2021. Br J Clin Pharmacol. 2021 Apr;87(4):2078–2088. doi: 10.1111/bcp.14619. Epub 2020 Dec 1. PMID: 33085781.
    OpenUrlCrossRefPubMed
  55. ↵
    Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF, 2020. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol 140:1–6. doi: 10.1007/s00401-020-02166-2.
    OpenUrlCrossRefPubMed
  56. ↵
    Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, Holden SJ, Raber J, Banks WA, Erickson MA, 2020. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci 24:368–378. doi: 10.1038/s41590-020-0778-2.
    OpenUrlCrossRefPubMed
  57. ↵
    Salguero FJ, White AD, Slack GS, Fotheringham SA, Bewley KR, Gooch KE, Longet S, Humphries HE, Watson RJ, Hunter L, Ryan KA, Hall Y, Sibley L, Sarfas C, Allen L, Aram M, Brunt E, Brown P, Buttigieg KR, Cavell BE, Cobb R, Coombes NS, Darby A, Daykin-Pont O, Elmore MJ, Garcia-Dorival I, Gkolfinos K, Godwin KJ, Gouriet J, Halkerston R, Harris DJ, Hender T, Ho CMK, Kennard CL, Knott D, Leung S, Lucas V, Mabbutt A, Morrison AL, Nelson C, Ngabo D, Paterson J, Penn EJ, Pullan S, Taylor I, Tipton T, Thomas S, Tree JA, Turner C, Vamos E, Wand N, Wiblin NR, Charlton S, Dong X, Hallis B, Pearson G, Rayner EL, Nicholson AG, Funnell SG, Hiscox JA, Dennis MJ, Gleeson FV, Sharpe S, Carroll MW, 2021. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat Commun 12(1):1260. doi: 10.1038/s41467-021-21389-9.
    OpenUrlCrossRef
  58. ↵
    Saura-Martinez H, Al-Saadi M, Stewart JP, Kipar K, 2021. Sheep-associated malignant catarrhal fever: role of latent virus and macrophages in vasculitis. Vet Pathol 58(2): 332–345. doi: 10.1177/0300985820978310.
    OpenUrlCrossRef
  59. ↵
    Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, de Bree GJ, Bulle EB, Aronica EM, Florquin S, Fronczek J, Heunks LMA, de Jong MD, Guo L, du Long R, Lutter R, Molenaar PCG, Neefjes-Borst EA, Niessen HWM, van Noesel CJM, Roelofs JJTH, Snijder EJ, Soer EC, Verheij J, Vlaar APJ, Vos W, van der Wel NN, van der Wal AC, van der Valk P, Bugiani M, 2020. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 1(7):e290–e299. doi: 10.1016/S2666-5247(20)30144-0.
    OpenUrlCrossRefPubMed
  60. ↵
    Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JL, Padera RF Jr., Sabeti P, 2020. Neuropathological features of Covid-19. N Engl J Med 383(10):989–992. doi: 10.1056/NEJMc2019373.
    OpenUrlCrossRefPubMed
  61. ↵
    Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, Lu P, Weizman OE, Liu F, Dai Y, Szigeti-Buck K, Yasumoto Y, Wang G, Castaldi C, Heltke J, Ng E, Wheeler J, Alfajaro MM, Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazmi SAJ, Zhang K, Wilen CB, Horvath TL, Plu I, Haik S, Thomas JL, Louvi A, Farhadian SF, Huttner A, Seilhean D, Renier N, Bilguvar K, Iwasaki A, 2021. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 218(3):e20202135. doi: 10.1101/2020.06.25.169946
    OpenUrlCrossRef
  62. ↵
    Steiner I, Spivack JG, Deshmane SL, Ace CI, Preston CM, Fraser NW, 1990. A herpes simplex virus type 1 mutant containing a nontransinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J Virol 64:1630–1638. doi: 10.1128/JVI.64.4.1630-1638.1990.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Swanson PA 2nd, McGavern DB, 2015. Viral diseases of the central nervous system. Curr Opin Virol 11:44–54. doi: 10.1016/j.coviro.2014.12.009.
    OpenUrlCrossRefPubMed
  64. ↵
    Tremblay ME, Madore C, Bordeleau M, Tian L, Verkhratsky A, 2020. Neuropathobiology of COVID-19: The role for glia. Front Cell Neurosci 14:592214. doi: 10.3389/fncel.2020.592214.
    OpenUrlCrossRef
  65. ↵
    Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H, 2020. Endothelial cell infection and endotheliitis in COVID-19. The Lancet 395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5.
    OpenUrlCrossRefPubMed
  66. ↵
    Vargas G, Medeiros Geraldo LH, Gedeão Salomão N, Viana Paes M, Regina Souza Lima F, Carvalho Alcantara Gomes F, 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells: Insights and perspectives. Brain Behav Immun Health 7:100127. doi: 10.1016/j.bbih.2020.100127.
    OpenUrlCrossRef
  67. ↵
    von Weyhern CH, Kaufmann I, Neff F, Kremer M, 2020. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet 395(10241):e109. doi: 10.1016/S0140-6736(20)31282-4.
    OpenUrlCrossRefPubMed
  68. ↵
    Wang Q, Ding SL, Li Y, Royall J, Feng D, Lesnar P, Graddis N, Naeemi M, Facer B, Ho A, Dolbeare T, Blanchard B, Dee N, Wakeman W, Hirokawa KE, Szafer A, Sunkin SM, Oh SW, Bernard A, Phillips JW, Hawrylycz M, Koch C, Zeng H, Harris JA, Ng L, 2020. The Allen Mouse Brain Common Coordinate Framework: A 3D reference atlas. Cell 181(4):936–953.e20. doi: 10.1016/j.cell.2020.04.007.
    OpenUrlCrossRefPubMed
  69. ↵
    Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Riter JH, Kang L-I, Dort S, Robichaud A, Head R, Holtzmann MJ, Diamond MS, 2020. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nature Immunol 21:1327–1335. doi: 10.1038/s41590-020-0778-2.
    OpenUrlCrossRefPubMed
  70. ↵
    Yinda CK, Port JR, Bushmaker T, Offei Owusu I, Purushotham JN, Avanzato VA, Fischer RJ, Schulz JE, Holbrook MG, Hebner MJ, Rosenke R, Thomas T, Marzi A, Best SM, de Wit E, Shaia C, can Doremalen N, Munster VJ, 2021. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog 17(1): e1009195. doi: 10.1371/journal.ppat.1009195.
    OpenUrlCrossRef
  71. Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, Liu M, Zhao X, Xie Y, Yang Y, Zhang S, Fan Z, Dong J, Yuan Z, Ding Z, Zhang Y, Hu L, 2020. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol 13(1):120. doi: 10.1186/s13045-020-00954-7.
    OpenUrlCrossRef
  72. ↵
    Zheng J, Wong LYR, Li K, Verma AK, Ortiz ME, Wohlford-Lenane C, Leidinger MR, Knudson CM, Meyerholz DK, McCray Jr PB, Perlman S, 2021. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589:603–607. doi: 10.1038/s41586-020-2943-z.
    OpenUrlCrossRef
Back to top
Posted April 16, 2021.
Download PDF
Email
Viral neuroinvasion and neurotropism without neuronal damage in the hACE2 mouse model of COVID-19
Frauke Seehusen, Jordan J. Clark, Parul Sharma, Krishanthi Subramaniam, Sabina Wunderlin Giuliani, Grant L. Hughes, Edward I. Patterson, Benedict D. Michael, Andrew Owen, Julian A. Hiscox, James P. Stewart, Anja Kipar
bioRxiv 2021.04.16.440173; doi: https://doi.org/10.1101/2021.04.16.440173
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area